Lyell Immunopharma (LYEL) Capital Expenditure: History & Chart

Lyell Immunopharma, Inc.(LYEL)

Biotechnology · South San Francisco, CA

$8.61-0.46 (-5.07%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Lyell Immunopharma, Inc.

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company’s lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; and CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

South San Francisco, CA

161 employees

www.lyell.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Lynn Seely

View full financials

Capital Expenditures

The latest quarterly capex is −$256.00 Thousand. Capital Expenditures (CapEx) represents spending on physical assets like property, plant, equipment, and technology infrastructure. It's the investment in the company's future productive capacity.

Q2 FY2026 (2026-06-30).

Depreciation|PP&E|Free Cash Flow|Acquisitions|Cash Flow

CapEx

LYEL CapEx

$-256000.00

Reported quarterly capital expenditures; no daily interpolation. Q2 FY2026 (2026-06-30): $-256000.00.

+96.28% over 10Y

Current CapEx

−$256.00K

−$256.00 Thousand

Q2 FY2026 · 2026-06-30

QoQ Growth

N/A

Historical Data

Quarters of data available

Quarterly CapEx History

Period	CapEx	QoQ Growth	YoY Growth
Q2 FY2026Period end 2026-06-30	−$256.00K	N/A	-52.38%
Q1 FY2026Period end 2026-03-31	−$89.00K	+70.72%	+63.82%
Q4 FY2025Period end 2025-12-31	−$304.00K	N/A	N/A
Q3 FY2025Period end 2025-09-30	−$62.00K	+63.10%	N/A
Q2 FY2025Period end 2025-06-30	−$168.00K	+31.71%	+49.24%
Q1 FY2025Period end 2025-03-31	−$246.00K	N/A	N/A
Q4 FY2024Period end 2024-12-31	−$44.00K	N/A	N/A
Q3 FY2024Period end 2024-09-30	−$59.00K	+82.18%	+69.74%
Q2 FY2024Period end 2024-06-30	−$331.00K	N/A	+64.52%
Q1 FY2024Period end 2024-03-31	−$30.00K	N/A	+98.04%
Q4 FY2023Period end 2023-12-31	−$25.00K	+87.18%	+99.45%
Q3 FY2023Period end 2023-09-30	−$195.00K	+79.10%	+93.01%
Q2 FY2023Period end 2023-06-30	−$933.00K	+39.14%	+86.99%
Q1 FY2023Period end 2023-03-31	−$1.53M	+66.54%	+84.25%
Q4 FY2022Period end 2022-12-31	−$4.58M	-64.17%	+55.38%
Q3 FY2022Period end 2022-09-30	−$2.79M	+61.07%	+75.94%
Q2 FY2022Period end 2022-06-30	−$7.17M	+26.33%	+70.67%
Q1 FY2022Period end 2022-03-31	−$9.73M	+5.21%	+49.28%
Q4 FY2021Period end 2021-12-31	−$10.27M	+11.48%	+58.73%
Q3 FY2021Period end 2021-09-30	−$11.60M	+52.55%	+8.24%
Q2 FY2021Period end 2021-06-30	−$24.45M	-27.39%	-245.39%
Q1 FY2021Period end 2021-03-31	−$19.19M	+22.87%	-178.88%
Q4 FY2020Period end 2020-12-31	−$24.88M	-96.83%	N/A
Q3 FY2020Period end 2020-09-30	−$12.64M	-78.60%	N/A
Q2 FY2020Period end 2020-06-30	−$7.08M	-2.86%	N/A
Q1 FY2020Period end 2020-03-31	−$6.88M	N/A	N/A

Growth uses unique fiscal quarters. Missing or ambiguous prior periods render N/A.

Data as of June 30, 2026